RhumbLine Advisers’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.01M | Buy |
215,691
+23,410
| +12% | +$109K | ﹤0.01% | 2247 |
|
|
2025
Q1 | $1.06M | Buy |
192,281
+11,317
| +6% | +$62.1K | ﹤0.01% | 2146 |
|
|
2024
Q4 | $613K | Buy |
180,964
+7,408
| +4% | +$25.1K | ﹤0.01% | 2535 |
|
|
2024
Q3 | $495K | Sell |
173,556
-16,414
| -9% | -$46.8K | ﹤0.01% | 2702 |
|
|
2024
Q2 | $427K | Buy |
189,970
+12,332
| +7% | +$27.7K | ﹤0.01% | 2784 |
|
|
2024
Q1 | $393K | Buy |
177,638
+6,346
| +4% | +$14K | ﹤0.01% | 2808 |
|
|
2023
Q4 | $403K | Sell |
171,292
-2,516
| -1% | -$5.91K | ﹤0.01% | 2793 |
|
|
2023
Q3 | $323K | Sell |
173,808
-81
| -0% | -$151 | ﹤0.01% | 2890 |
|
|
2023
Q2 | $456K | Buy |
173,889
+1,038
| +0.6% | +$2.72K | ﹤0.01% | 2746 |
|
|
2023
Q1 | $282K | Buy |
172,851
+6,990
| +4% | +$11.4K | ﹤0.01% | 2635 |
|
|
2022
Q4 | $221K | Buy |
165,861
+3,145
| +2% | +$4.19K | ﹤0.01% | 2774 |
|
|
2022
Q3 | $254K | Buy |
162,716
+11,102
| +7% | +$17.3K | ﹤0.01% | 2804 |
|
|
2022
Q2 | $233K | Buy |
+151,614
| New | +$233K | ﹤0.01% | 2874 |
|
|
2021
Q2 | – | Sell |
-41,774
| Closed | -$188K | – | 3117 |
|
|
2021
Q1 | $188K | Sell |
41,774
-1,426
| -3% | -$6.42K | ﹤0.01% | 2844 |
|
|
2020
Q4 | $213K | Buy |
43,200
+5,630
| +15% | +$27.8K | ﹤0.01% | 2813 |
|
|
2020
Q3 | $223K | Sell |
37,570
-7,883
| -17% | -$46.8K | ﹤0.01% | 2640 |
|
|
2020
Q2 | $121K | Buy |
45,453
+14,269
| +46% | +$38K | ﹤0.01% | 2923 |
|
|
2020
Q1 | $61K | Hold |
31,184
| – | – | ﹤0.01% | 2842 |
|
|
2019
Q4 | $220K | Buy |
31,184
+349
| +1% | +$2.46K | ﹤0.01% | 2719 |
|
|
2019
Q3 | $303K | Sell |
30,835
-57
| -0.2% | -$560 | ﹤0.01% | 2581 |
|
|
2019
Q2 | $353K | Buy |
30,892
+7,831
| +34% | +$89.5K | ﹤0.01% | 2521 |
|
|
2019
Q1 | $232K | Buy |
+23,061
| New | +$232K | ﹤0.01% | 2681 |
|